MetaCap

Amneal Pharmaceuticals (AMRX) vs Cytokinetics (CYTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amneal Pharmaceuticals (AMRX) has outperformed Cytokinetics (CYTK) over the past year, gaining 76.7% versus a loss of 22.4%. Over five years, AMRX leads with a +396.9% price change compared with +30.1% for CYTK. Amneal Pharmaceuticals is the larger company by market cap ($7.36 billion vs $7.07 billion), about 1.0 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +8.0%).

Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -891.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRX+76.74%CYTK-22.40%
+88%+30%-28%
Nov 21, 20251 yearNov 20, 2026
AMRX+357.14%CYTK+24.28%
+387%+147%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRX versus CYTK key metrics
MetricAMRXCYTK
Share price$21.12$50.78
Market cap$7.36B$7.07B
1-day change-1.26%-1.32%
YTD return+67.62%-20.08%
1-year return+76.74%-22.40%
5-year return+396.94%+30.11%
P/E ratio (TTM)52.80—
Forward P/E17.13—
EPS (TTM)$0.40$-6.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.02B$88.04M
Revenue growth (YoY)+8.05%+376.56%
Net income (latest FY)$72.06M$-784.96M
Gross margin36.88%—
Operating margin13.05%-695.44%
Net margin2.39%-891.60%
52-week high$22.13$88.31
52-week low$11.71$50.32
Distance from 52-week high-4.54%-42.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+15.01%+115.48%
Average volume3.16M2.02M
Shares outstanding348.41M139.30M
Employees8,700673
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMRX has outperformed CYTK by 99.1 percentage points over the past year.
  • Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
  • Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +8.05%).

About Amneal Pharmaceuticals

AMRX stock →

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees

About Cytokinetics

CYTK stock →

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees

AMRX vs CYTK FAQ

Which is bigger, Amneal Pharmaceuticals or Cytokinetics?

Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $7.36B compared with $7.07B for Cytokinetics (CYTK).

Which stock has performed better over the past year, AMRX or CYTK?

AMRX returned +76.74% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.

Are Amneal Pharmaceuticals and Cytokinetics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons